Latest Breaking News On - Clinical data program - Page 1 : comparemela.com

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Glasgow cityUnited kingdomUnited statesJenniferl taylor cousarKatherine smithJulian peiNational jewish healthDrug administrationExchange commissionCystic fibrosis foundationClinical data programPrincipal investigatorEuropean cystic fibrosis conferenceMolecular therapeuticsNational jewishWebcast details

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47?? European Cystic Fibrosis Conference

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47?? European Cystic Fibrosis Conference
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Glasgow cityUnited kingdomUnited statesKatherine smithJenniferl taylor cousarJulian peiNational jewish healthCystic fibrosis foundationDrug administrationExchange commissionClinical data programPresent interim dataCystic fibrosisEuropean cystic fibrosisPrincipal investigatorEuropean cystic fibrosis conference

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

51 wet AMD patients with severe disease activity and high treatment burden were randomized to high or low dose 4D-150 or aflibercept control regimen4D-150 was well tolerated with a favorable.

United statesArshadm khananiDavid kirnRobert kimJulian peiKatherine smithCorporate communicationsProgram updatesExchange commissionGlobenewswire incClinical data programEuropean unionClinic researchSierra eye associatesD molecular therapeutics incMolecular therapeutics

4DMT Presents Positive Interim Data from Randomized Phase 2

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden.

United statesDavid kirnKatherine smithRobert kimJulian peiArshadm khananiClinic research at sierra eye associatesProgram updatesEuropean unionCorporate communicationsClinical data programExchange commissionMolecular therapeuticsChief executive officerChief medicalClinic research

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesJulian peiRobert kimDavid kirnArshadm khananiKatherine smithProgram updatesClinic research at sierra eye associatesCorporate communicationsEuropean unionClinical data programExchange commissionPositive interim dataRandomized phaseFavorable tolerabilityClinical activity